Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Clonidine reduces post-surgical risk of cardiovascular death in non-cardiac surgery

27.07.2004


Patients with or at risk for heart disease who take the anti-hypertensive drug clonidine before non-cardiac surgery can significantly reduce the risk of complications and death due to inadequate blood flow to the heart, according to a study by UCSF researchers at the San Francisco Veterans Affairs Medical Center.



The findings add a second drug to the list of inexpensive preventive measures available to these patients before non-cardiac surgery. In 1998 the same UCSF/SFVAMC researchers identified the beta blocker atenolol as an effective preventive measure for this patient group. The clonidine research is reported in the August 2004 issue of the journal Anesthesiology.

"In the earlier study we found an inexpensive way to reduce the incidence of death due to surgery. Now we have found another drug to do the same thing," said lead researcher Arthur Wallace, MD, PhD, UCSF associate professor of anesthesia and perioperative care and staff anesthesiologist at the SFVAMC.


The clonidine study focused on 190 male patients scheduled to undergo non-cardiac surgery who had been diagnosed with coronary artery disease or had at least two of five risk factors for cardiac disease: age 60 or older, hypertension, smoking within a year, cholesterol of 240 or greater or diabetes. Scheduled surgeries included orthopedic, head and neck, abdominal and others.

Of the patients, 125 received a .2 mg oral tablet of clonidine the night before surgery, a transdermal patch of clonidine the night before surgery and a .2 mg tablet one hour before surgery. A control group of 65 received placebos. After follow-ups of three days, 14 days, 30 days and two years, the clonidine group showed a death rate of 1 percent compared to 6 percent for the placebo group. After two years, the death rate of the clonidine group was 15 percent compared to 29 percent for the placebo group.

Patients were monitored for episodes of blocked blood flow using Holter electrocardiogram recorders--before, on the day of, and up to seven days after surgery. They also received electrocardiograms to measure the heartbeat every day for the first seven days after surgery and whenever necessary due to shortness of breath, chest pain or loss of consciousness. Blood pressure was recorded continuously from one hour before surgery to one hour following surgery, and blood samples were analyzed for presence of heart enzymes and clonidine concentrations.

Researchers found that patients who had received clonidine showed no evidence of myocardial ischemiac events (inadequate blood flow to the heart) before surgery compared to 5 percent for those who had received placebos.

On the day of surgery and up to three days after surgery only 14 percent of clonidine patients experienced such events, compared to 31 percent for placebo patients. After 30 days, one (.8 percent) of the clonidine patients had died compared to four (6.2 percent) of placebo patients. In a two-year follow up, 19 (15 percent) of the clonidine group had died compared to 19 (29 percent) of the placebo group.

"For these patients, myocardial ischemia is associated with a nine-fold increase in cardiac complications before hospital discharge and a two-fold greater two-year risk of death after surgery. Drug therapy to prevent blocked arteries prevents the start of a chain of events leading to heart attack and death," said Wallace.

Researchers conclude that patients with or at risk for coronary artery disease who undergo non-cardiac surgery should be considered for pre-surgery treatment with either atenolol, which is a beta blocker, or clonidine, which is an alpha2-agonist, as these substances have been shown to prevent symptoms of cardiac disease and death. A beta blocker blocks stress hormones produced in the brain from stimulating the heart. An alpha2-agonist decreases the release of stress hormones produced in the brain.

Six million Americans with or at risk for cardiac disease undergo non-cardiac surgery each year. "The current study clearly demonstrates a significant difference in 30-day and two-year mortality using a prophylactic and anti-ischemic therapy," the researchers wrote.

While the study does not indicate which treatment is superior, protocols for using both drugs are included in joint surgery guidelines of the American Heart Association and the American College of Cardiology.

The study was funded by the American Heart Association, Veterans Administration Merit Review Funding, Ischemia Research and Education Foundation and the Northern California Institute for Research and Education (NCIRE), a federal nonprofit foundation affiliated with the SFVAMC.

Study co-investigators are Daniel Galindez, MD, and Ali Salahieh, BS, research associates, Anesthesiology Service, SFVAMC; and Elizabeth L. Layug, MD, research associate; Eleanor A. Lazo, MD, research fellow; Kathy A. Haratonik, BA, research technician; and Dennis M. Boisvert, MS, and David Kardatzke, PhD, statisticians, all of the Ischemia Research and Education Foundation.

Joan Aragone | EurekAlert!
Further information:
http://www.ucsf.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>